Miha Homar receives the Minařik Award for his contributions to the development of the pharmaceutical profession

  • Miha Homar, Ph.D., a senior scientist from the  Development Center Slovenia, received the 2021 Minařik Award for his  exceptionally committed research work, integration and transfer of knowledge  between industry and university, and comprehensive and active collaboration  with the Society. 
  • The  Minařik Award is the highest award bestowed by the Slovenian Pharmaceutical  Society for longstanding and exceptional contributions to pharmaceutical  development.
  • The award confirms the longstanding efforts of  Novartis in Slovenia to create an empowered, curious and inspiring  organizational culture, in which employees demonstrate excellence at every  step.
20. 9. 2021

Miha Homar, Ph.D., a senior scientist from the Development Center Slovenia, received the 2021 Minařik Award bestowed by the Slovenian Pharmaceutical Society. He received the award for his longstanding and exceptional contributions to pharmaceutical development, his dedicated research work, integration and transfer of knowledge between industry and university, and his comprehensive and active collaboration with the Society.

Upon receiving the highest award in the pharmaceutical field in Slovenia, Miha Homar, Ph.D., said: “I am extremely grateful that  the Slovenian Pharmaceutical Society has recognized my hard work and dedication. On this occasion, I would like to thank Novartis in Slovenia for knowing  exactly how to encourage its employees to unleash our potential. I believe that  with such a culture and such colleagues we can celebrate many new successes  together and overcome even the most demanding challenges through collaboration,  perseverance and courage.”

Miha Homar, Ph.D., received his doctorate in 2007 from the Faculty of Pharmacy at the University of Ljubljana. Even as an employee of Novartis in Slovenia he still collaborates with the faculty, mainly as a co-mentor for numerous master's theses, thus making an important contribution to the transmission of knowledge to younger generations. His innovativeness is reflected in articles published in the field of pharmaceutical technology and in the co-authorship of two granted patents and eight patent applications. Miha Homar is an indispensable part of the Novartis team in Slovenia, as his innovativeness, incisiveness and perseverance represent the key values of Novartis culture.

* * *

Novartis  is the leading provider of medicines in Slovenia, where Lek d.d., Novartis Pharma Services Inc., Podružnica v Sloveniji and Sandoz d.d., operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Over the last nine years, the company has created more than 3,350 new job opportunities, making us one of the biggest employers in Slovenia. Novartis invested in Slovenia more than EUR 2.7 billion since 2003.

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2020 sales of USD 9.6 billion.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Gregor  Makuc
Communications & External Engagement
Lek Pharmaceuticals d.d.
Phone: +386 1 580 22 43